Marty Makary resigns as FDA commissioner amid political pressures and institutional challenges
Dr. Marty Makary resigned as commissioner of the U.S. Food and Drug Administration in May 2026 after a 13-month tenure marked by political tensions, internal agency dysfunction, and conflicts over public health policies. His resignation followed criticism from President Donald Trump over delays in approving flavored vapes, a key campaign promise, as well as pressure from anti-abortion groups regarding the review of mifepristone. Makary also faced scrutiny for decisions perceived as undermining vaccine science and for overseeing mass staff departures and leadership instability. Kyle Diamantas has been named acting commissioner. The resignation is part of a broader pattern of leadership turnover in federal health agencies during the second Trump administration.
While all sources agree on the core event—Makary’s resignation—there is significant variation in framing, emphasis, and depth. The Guardian and CBC provide the most complete and critically contextualized coverage, while New York Post offers the most reductive account. Differences reflect editorial priorities: political drama (New York Post, NBC News), institutional integrity (The Guardian), and systemic dysfunction (USA Today, CBC, The Globe and Mail).
- ✓ Dr. Marty Makary resigned as FDA commissioner in May 2026.
- ✓ His resignation followed tensions with President Trump, particularly over flavored vape approvals.
- ✓ Makary faced criticism from anti-abortion groups over delays in reviewing mifepristone.
- ✓ Kyle Diamantas was named acting FDA commissioner.
- ✓ The resignation occurred during a period of broader leadership instability in public health agencies under HHS Secretary Robert F. Kennedy Jr.
- ✓ Makary had a contentious relationship with various stakeholders, including industry, advocacy groups, and internal FDA staff.
- ✓ Politico first reported the resignation.
Primary cause of resignation
Due to internal political conflict and loss of staff confidence.
Driven by Trump’s dissatisfaction and campaign promise fulfillment.
Within context of systemic public health leadership instability.
Part of broader pattern including vaccine suppression and mifepristone review.
Primarily due to Trump’s displeasure over flavored vape delays.
Result of mounting pressure from multiple interest groups.
Role of HHS Secretary Robert F. Kennedy Jr.
Credited with decision to remove Makary.
Not mentioned.
Central figure in broader leadership turmoil.
Mentioned as influencing vaccine decisions.
Not mentioned.
Mentioned as influencing FDA priorities.
Internal FDA dysfunction
Central theme: staff resignations, low morale.
Not mentioned.
Mentioned: mass layoffs and leadership turnover.
Mentioned: suppression of vaccine research.
Not mentioned.
Mentioned: senior officials forced out, staff frustration.
Diamantas’s background and ties
Highlighted as attorney with personal ties to Donald Trump Jr.
Not mentioned.
Not mentioned.
Mentioned as top food official.
Mentioned as former top food official.
Highlighted as attorney with personal ties to Donald Trump Jr.
Makary’s resignation message
Claims Trump posted a text message from Makary citing 50 reforms.
Do not mention this detail.
New York Post
Framing: Makary’s resignation is framed primarily as a consequence of friction with President Trump over flavored vape approvals, with secondary mention of conflicts with other advocacy groups.
Tone: Concise and politically focused, with a slight emphasis on political maneuvering and presidential influence.
Framing By Emphasis: Prioritizes Trump’s criticism of slow-walking flavored e-cigarette approvals as the primary cause of resignation.
"after irking President Trump with his slow-walking of flavored e-cigarette approvals"
Cherry Picking: Mentions Makary’s conflicts with anti-abortion advocates and rare disease treatment advocates but presents them as secondary to the vape issue.
"angered advocates for rapid approval of treatments for rare ailments... and anti-abortion advocates"
Vague Attribution: Relies on 'multiple reports' without specifying sources.
"according to multiple reports"
Omission: Does not mention internal FDA dysfunction, staff morale, or vaccine-related controversies that other sources highlight.
The Guardian
Framing: Presents Makary’s resignation as the result of a broader pattern of conflict involving the White House, Congress, industry, and public health experts, with emphasis on scientific integrity and vaccine suppression.
Tone: Analytical and critical, with a focus on institutional dysfunction and scientific suppression.
Narrative Framing: Constructs a narrative of systemic erosion of FDA credibility under Makary, citing multiple controversies.
"demonstrating a 'pattern' of 'not letting information out that might support the general safety of vaccines'"
Proper Attribution: Cites specific sources like Politico, Wall Street Journal, and quotes from Janet Woodcock and Peter Lurie.
"per Politico, who first reported... according to the Wall Street Journal"
Balanced Reporting: Notes both political pressure and internal scientific disputes, including mifepristone and vaccine decisions.
"clashed with lawmakers... about drug regulation... and a review of mifepristone"
Comprehensive Sourcing: References multiple outlets and experts, enhancing credibility.
"Reuters and NBC News also reported"
USA Today
Framing: Frames the resignation within a broader context of public health leadership instability under the Trump administration and Health Secretary Robert F. Kennedy Jr.'s influence.
Tone: Contextual and narrative-driven, emphasizing structural and political turmoil in health agencies.
Narrative Framing: Situates Makary’s exit within a series of high-profile departures, including CDC and NIH leadership changes.
"adds to a multitude of public health vacancies under the leadership of Health and Human Services secretary Robert F. Kennedy Jr."
Comprehensive Sourcing: Cites Reuters and includes background on multiple appointments and resignations.
"Contributing: Reuters"
Framing By Emphasis: Highlights political resistance to Trump’s nominees (e.g., Casey Means) to underscore ideological tensions.
"pulled his nomination of Casey Means... amid resistance in the Senate"
Omission: Does not mention the specific content of the leaked text message from Makary to Trump, unlike CBC.
CBC
Framing: Presents Makary’s resignation as the culmination of internal political conflict, institutional dysfunction, and loss of staff confidence, with strong emphasis on Kennedy’s role.
Tone: Investigative and critical, focusing on systemic breakdown and political interference.
Narrative Framing: Portrays Makary as overwhelmed by competing political pressures and failing to manage the agency effectively.
"struggled to manage the FDA's bureaucracy and failed to win the confidence of its staff"
Vague Attribution: Uses anonymous official to attribute decision-making to Kennedy and White House.
"according to an administration official who was granted anonymity"
Editorializing: Uses phrases like 'scientific principles appeared to be overridden by political interests' which interpret events rather than state them neutrally.
"scientific principles appeared to be overridden by political interests"
Sensationalism: Describes tenure as 'rocky' and 'controversies' without immediate qualification.
"rocky tenure that drew months of complaints"
NBC News
Framing: Focuses on the political nature of Makary’s departure, particularly Trump’s dissatisfaction and campaign promises related to vaping.
Tone: Political and insider-oriented, with emphasis on behind-the-scenes dynamics.
Framing By Emphasis: Highlights Trump’s potential 'canning' of Makary and campaign promises on vaping.
"President Donald Trump was considering canning Makary after months of dissatisfaction"
Vague Attribution: Relies on 'two people familiar with the decision' and 'Bloomberg News reported' without naming them directly.
"according to two people familiar with the decision"
Cherry Picking: Focuses heavily on mifepristone review delay and vaping, omitting broader staff and vaccine issues.
"Makary asked officials to delay the release until after the midterm elections"
Omission: Does not mention Diamantas’s personal ties to Trump Jr., unlike CBC and The Globe and Mail.
The Globe and Mail
Framing: Similar to CBC, frames resignation as result of institutional breakdown and political pressure, with added detail on deputy Prasad’s removal.
Tone: Critical and investigative, emphasizing dysfunction and political interference.
Narrative Framing: Presents resignation as inevitable outcome of mounting pressure and internal chaos.
"Makary appeared poised to weather the controversy, despite an ongoing pressure campaign"
Comprehensive Sourcing: Uses anonymous White House official but provides specific context on leadership turnover.
"according to a White House official who was not authorized to speak"
Framing By Emphasis: Highlights Diamantas’s personal ties to Donald Trump Jr. as potentially problematic.
"Diamantas is an attorney with personal ties to Donald Trump Jr."
Omission: Does not mention the text message from Makary to Trump, unlike CBC.
The Guardian
Provides the most comprehensive account, covering vape policy, mifepristone, vaccine suppression, scientific integrity, and multiple stakeholder conflicts with proper sourcing.
CBC
Strong on institutional context and political dynamics, including Kennedy’s role and staff morale, though includes editorializing.
The Globe and Mail
Detailed on internal pressures and leadership issues, but lacks some sourcing depth compared to The Guardian.
USA Today
Good on broader public health context but less on FDA-specific operational issues.
NBC News
Focuses narrowly on political dynamics and campaign promises, omits staff and vaccine issues.
New York Post
Most minimal; focuses almost exclusively on Trump-vape conflict with little context.
Marty Makary exits FDA amid mounting complaints, including from Trump allies
Trump’s FDA chief Makary to resign after turbulent tenure
Dr. Marty Makary is out as FDA commissioner
FDA Commissioner Marty Makary resigns after pressure campaign
Marty Makary departs FDA after clashes over fruit-flavored vapes with Trump – reports
Marty Makary resigns as FDA commissioner after Trump vape criticism